The Motley Fool

Why I’d buy this under-the-radar dividend stock instead of Vodafone Group plc

With a dividend yield of 6.2%, shares in Vodafone (LSE: VOD) are understandably tempting for income investors. But there is one major question to consider: does the telecoms giant have what it takes to deliver market-beating returns for investors?

Share price down 6%

The group’s share price is down 6% from a year ago, despite steady organic growth in service revenues and improving free cash flow. Progress has been slow, but Vodafone seems to be getting there. Although overall group revenues in the last financial year dipped by 4.4%, operating profits soared by 182% to €3.7bn as free cash flow more than doubled to €4.1bn.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Continuing with the momentum into 2017, first quarter service revenues grew by 2.2% to €10.8bn, with good growth across Continental Europe — particularly in Italy and Spain, where it had come under intense pressure from price cutting by its rivals. This slow but steady progress, however, does not seem to have been well received by investors.

Cut-throat competition

And it’s probably for good reasons too, given that Vodafone continues to face cut-throat competition from the industry. Its rivals are keeping prices low, while ramping up spending on new, faster networks and multi-play solutions. Vodafone is having a particularly difficult time in the UK, where it lacks its own pay-TV services — with organic service revenues there falling by 3.2%, in contrast to positive growth in its other European markets.

Add to that the big investments planned for the next few years, Vodafone seems set to face a challenging road ahead. To make matters worse, the company’s debt pile is fast rising, with net debt of £31.2bn, just while new mobile spectrum auctions are looming. This means that, looking ahead, future returns could be less than enthusiastic as these pressures crimp future dividend growth and threaten the mobile network operator’s uncertain recovery.

What’s more, valuations aren’t looking too tempting either, with shares trading on a forecast P/E of 28.

Good momentum

Instead Chesnara (LSE: CSN), the life and pensions consolidator, might be a better buy for dividend investors. The Preston-based company is showing good momentum following the completion of its latest acquisition, Legal and General Nederland, which has since been rebranded as Scildon.

Its Economic Value, a key measure of the insurer’s underlying worth, climbed by almost £100m in the first six months of 2017, to £700m, while group cash generation rose from £13.6m last year to £46.2m. The insurer also boasted of strong financial foundations as its solvency ratio remained resilient, at 143%, despite the impact of recent acquisitions.

Looking ahead, City analysts expect Chesnara to pay shareholders a dividend of 20p a share, which gives shareholders an appealing prospective yield of 5%. The company is highly cash generative and easily affords its annual dividends internally, with dividend cover expected to rise to nearly two times this year.

Valuations are also attractive as shares in the company trade at a 15% discount to its Economic Value, with a forward P/E of just 10.3 indicating that it offers substantial upward re-rating potential.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US $12.3 TRILLION out of thin air…

And if you click here, we’ll show you something that could be key to unlocking 5G’s full potential...

It’s just ONE innovation from a little-known US company that has quietly spent years preparing for this exact moment…

But you need to get in before the crowd catches onto this ‘sleeping giant’.

Click here to learn more.

Jack Tang has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.